Comparative Pharmacology
Head-to-head clinical analysis: DEXTROAMPHETAMINE SULFATE versus XELSTRYM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROAMPHETAMINE SULFATE versus XELSTRYM.
DEXTROAMPHETAMINE SULFATE vs XELSTRYM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases extracellular levels of norepinephrine and dopamine by blocking reuptake and promoting release from presynaptic terminals, via trace amine-associated receptor 1 (TAAR1) agonism and vesicular monoamine transporter 2 (VMAT2) inhibition.
XELSTRYM (dextroamphetamine transdermal system) is a sympathomimetic amine that increases synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals.
5-60 mg/day orally divided every 4-6 hours, starting at 5 mg once or twice daily.
Initial: one 9-mg patch applied to the hip once daily; titrate weekly in 4.5-mg increments to desired effect; maximum dose: 18 mg/day.
None Documented
None Documented
9-11 hours (adults); clinical context: twice-daily dosing achieves steady-state in ~2-3 days.
Mean terminal elimination half-life of dexmethylphenidate is approximately 2-3 hours in children and adolescents, with no significant accumulation at steady state; clinical effects correlate with plasma concentrations.
Primarily renal (30-50% unchanged at acidic pH, less at alkaline pH); ~50% as metabolites (mostly deaminated and hydroxylated); minimal biliary/fecal.
Renal (90% as unchanged drug and metabolites, primarily dehydrodexmethylphenidate and inactive metabolites); minor biliary/fecal elimination (<5%)
Category D/X
Category C
CNS Stimulant
CNS Stimulant